Future Innovation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Future Innovation
Presidents of leading associations offer views on the industry's future.

Pharmaceutical Technology
Volume 36, Issue 7, pp. 142, 141

David Y. Mitchell, PhD, President, American Association of Pharmaceutical Scientists (AAPS)



"The pharmaceutical sciences are moving towards a new era and continue to adapt, evolve, and thrive despite some well-documented growing pains. In the US and EU, there has been a pronounced shift to produce a leaner R&D process in large pharma, with a move in workforce towards smaller companies, CROs, CMOs, and biotechnology startups. Whereas, in Asia Pacific, pharma is expanding their footprint with clinical trials and new manufacturing sites, new government and private industry technical centers to promote basic science research, and a goal of becoming one of the top research and marketing regions of the world.

"The industry now not only looks internally for new drug-development leads, but also towards smaller pharma, biotechnology companies, and academic institutions, with their focused research programs and their quick and nimble operations, to bring forth the potential medicines of tomorrow. Further, the pharma industry is expanding globally to leverage new markets and low-cost alternatives for drug development.

"AAPS would like to congratulate Pharmaceutical Technology on its 35th anniversary. We're looking forward to continuing our strong partnership as we navigate these changes that will impact of our industry for the next 35 years."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here